Please login to the form below

Not currently logged in
Email:
Password:
I have forgotten my password

Novartis Pharma

This page shows the latest Novartis Pharma news and features for those working in and with pharma, biotech and healthcare.

NICE rejects Novartis migraine treatment Aimovig

NICE rejects Novartis migraine treatment Aimovig

Aimovig has a list price of around £5, 000 per year, although Novartis has offered NICE a confidential discount. ... Haseeb Ahmad, Country President, Novartis UK. “If this decision remains unchanged patients will be denied access to the first licensed

Latest news

  • Novartis gets breakthrough tag from FDA for sickle cell drug Novartis gets breakthrough tag from FDA for sickle cell drug

    Latest pipeline therapy for painful blood disorder. A monthly antibody drug to treat sickle cell disease, developed by Novartis, has won a coveted breakthrough designation from the FDA as it heads ... Novartis is hoping to file for approval of the

  • Pharma’s R&D productivity sinks to a new low Pharma’s R&D productivity sinks to a new low

    It’s no secret that smaller pharma and biotech firms have been able to achieve greater productivity compared to big pharma. ... Novartis, one of the big pharma pioneers in cell and gene therapy, disclosed last week that it is exploring a novel

  • Novartis buys CellforCure to bolster cell, gene therapy Novartis buys CellforCure to bolster cell, gene therapy

    The Swiss pharma giant has offered to buy CellforCure – which already has a contact to manufacture Kymriah (tisagenlecleucel) – from biotechnology group LFB for an undisclosed amount. ... It says the deal would “would bolster CAR-T cell therapy

  • Novartis withdraws EU filing for canakinumab Novartis withdraws EU filing for canakinumab

    said the data submitted by Novartis was "not robust enough" to show the drug’s efficacy in all patients who have had an MI. ... This is a markedly different picture to when Novartis reported encouraging data from its phase 3 CANTOS trial in 2017.

  • FDA fast tracks Novartis’ SMA gene therapy FDA fast tracks Novartis’ SMA gene therapy

    Novartis is expected to provide tough competition for Biogen and its first-to-market SMA treatment, Spinraza. ... AveXis' David Lennon. AveXis, a neurological genetic disease focused company that Novartis acquired for $8.7bn in April this year, developed

More from news
Approximately 6 fully matching, plus 456 partially matching documents found.

Latest Intelligence

  • Leo has its eyes on the prize Leo has its eyes on the prize

    We are in an era of great change and treatment advances,” says Gitte Aabo, CEO and President of Leo Pharma. ... It makes it very attractive not only for Leo but for big pharma companies such as Novartis and Celgene that are very active in this area.

  • Can value-based healthcare take off and reach for the skies? Can value-based healthcare take off and reach for the skies?

    they do badly,” added Mr Moran, who joined Novartis from McKinsey &Company as a strategic assistant to the CEO in January 2015. ... A one-off treatment, it comes with the hefty $475, 000 price tag - and a red rag to anti-pharma factions - but put

  • Bridging pharma’s digital gap Bridging pharma’s digital gap

    But in true pharma fashion, that leap was not without its side effects. ... What Novartis and all the other pharma companies are trying to do is distil the myriad content that they have available at their fingertips and transform it into something useful,

  • Are we #winning? Are we #winning?

    We’ve seen multiple online ‘TV’ channels launch from medical societies and congress; some (eg ASCO) have commoditised their assets, and - for example, with Novartis’ VivindaTV.com - pharma is now competing ... As this transformation continues at

  • Deal Watch December 2016 Deal Watch December 2016

    295. Novartis (Switzerland). Sun Pharma (India). Asset acquisition. Odomzo (sonidegib; hedgehog pathway inhibitor), approved in basal cell carcinoma. ... and Bicycle Therapeutics at $1bn, and the Purdue Pharma-Exicure deal, at $790m.

More from intelligence
Approximately 1 fully matching, plus 12 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 30 partially matching documents found.

Latest from PMHub

  • How do you define a biotech company?

    Johnson &Johnson and Pfizer are two of the largest pharma companies in the world by revenue but both have numerous biological therapies. ... This approach is particularly apparent in some of the recent examples of technology pioneered by biotech

  • Marketing strategy in complex environments

    Kulveer Singh and Mark Assenti talk through what this means for pharma strategists and their product lines. ... The last few years have seen influential scientific advances, resulting in subtle shifts in how pharma tackles disease treatment.

  • Experienced Healthcare Marketer Gareth Thurston, joins Cello Health Consulting

    Gareth has over 20 years’ experience in senior roles in a number of pharma companies, most recently at Novartis, where he spent seven years in various roles, including Brand Lead Opthalmology, ... biggest pharma companies.” Gareth will be based at

  • Cogora

    Circassia. GE Healthcare. GlaxoSmithKline. Grunenthal. Indivior. Mallinckrodt. Mylan. Nestle. Novartis. Novo Nordisk. ... Nutricia. Orion Pharma. Orphan Europe. Pfizer. Portola. Prostate Cancer UK. Primary Care Respiratory Society.

More from PMHub
Approximately 0 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
W2O Group

W2O Group is an integrated marketing agency with expertise in brand and digital strategy, creative development and communications services. We...

Latest intelligence

The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...
Digital applications are transforming the market access landscape
Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....
Escaping the spin cycle of sub-optimal launch
...

Quick links

Infographics

Multimedia